Drug Trial Radar · NCT04944992
A Study of Efinopegdutide (MK-6024) in Participants With Nonalcoholic Fatty Liver Disease (NAFLD) (MK-6024-001)
Last checked: Nov 19, 2026Latest source record: Nov 15, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
145
Actual
Start
Aug 4, 2021
Primary completion
Oct 19, 2022
Study completion Oct 19, 2022
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Jun 30, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The principal goal of this study is to determine the efficacy of efinopegdutide in liver fat reduction in participants with NAFLD. The primary hypotheses are that efinopegdutide is superior to semaglutide, or that efinopegdutide is superior to semaglutide by at least 10% with respect to mean relative reduction from baseline in liver fat content (LFC) after 24 weeks.
Conditions
- Nonalcoholic Fatty Liver Disease
- Nonalcoholic Steatohepatitis
Interventions
Efinopegdutide 20 mg/mLDrug
Subcutaneous injection in a dose-escalation administration of 2.4 mg, 5.0 mg, and 10.0 mg
Semaglutide 1.34 mg/mLDrug
Subcutaneous injection in a dose-escalation administration of 0.25 mg, 0.5 mg, and 1.0 mg
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean Relative Reduction From Baseline in Liver Fat Content (LFC) Measured by Magnetic Resonance Imaging-Estimated Proton Density Fat Fraction (MRI-PDFF), Evaluated by Blinded Independent Central Review (BICR) After 24 WeeksTime frame: Baseline and up to ~24 Weeks
- Percentage of Participants Who Experienced an Adverse Event (AE)Time frame: Up to ~29 weeks
- Percentage of Participants Who Discontinued Study Intervention Due to an AETime frame: Up to ~24 weeks
Locations
69 sites in 16 countries. Site status is shown where the registry gives one.
Catalina Research Institute, LLC ( Site 1939)
Montclair, California
Sweet Hope Research Specialty, Inc ( Site 1902)
Hialeah, Florida
Floridian Clinical Research, LLC ( Site 1950)
Miami Lakes, Florida
Sensible Healthcare, LLC ( Site 1903)
Ocoee, Florida
Lucas Research, Inc ( Site 1930)
Morehead City, North Carolina
Texas Clinical Research Institute ( Site 1910)
Arlington, Texas
Baylor College of Medicine-Advanced Liver Therapies ( Site 1960)
Houston, Texas
American Research Corporation at Texas Liver Institute ( Site 1920)
San Antonio, Texas
Clinical Trials of Texas, Inc. ( Site 1906)
San Antonio, Texas
IDIM - Instituto de Diagnóstico e Investigaciones Metabólicas ( Site 0107)
Buenos Aires, Argentina
CIPREC-Laboratorio ( Site 0104)
Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina
Instituto de Investigaciones Clínicas Mar del Plata ( Site 0101)
Mar del Plata, Buenos Aires, Argentina
Centro Medico Dra. Laura Maffei- Investigacion Clinica Aplicada ( Site 0105)
Buenos Aires, Buenos Aires F.D., Argentina
Westmead Hospital-Gastroenterology & Hepatology ( Site 0204)
Westmead, New South Wales, Australia
Flinders Medical Centre-Hepatology and Liver Transplant Medicine ( Site 0201)
Bedford Park, South Australia, Australia
Heritage Medical Research Clinic ( Site 0302)
Calgary, Alberta, Canada
Centre Hospitalier Universitaire Dijon Bourgogne - Hôpital F-ENDOCRINOLOGY-DIABETOLOGY ( Site 0401)
Dijon, Cote-d Or, France
centre hospitalier lyon sud-Endocrinologie, Diabète et Nutrition ( Site 0402)
Pierre-Bénite, Rhone, France
Rambam Health Care Campus-Liver disease unit ( Site 0704)
Haifa, Israel
Carmel Hospital-Liver Unit ( Site 0705)
Haifa, Israel
Shaare Zedek Medical Center-Liver Unit ( Site 0703)
Jerusalem, Israel
Rabin Medical Center ( Site 0701)
Petah Tikva, Israel
Sheba Medical Center-The Liver Diseases Center ( Site 0700)
Ramat Gan, Israel
Sourasky Medical Center-Gastroenterology and Liver Disease ( Site 0702)
Tel Aviv, Israel
Azienda Ospedaliero Universitaria ( Site 0803)
Modena, Italy
Azienda Ospedaliera Universitaria Integrata Verona - Ospedale Borgo Roma-Medicine ( Site 0804)
Verona, Italy
Policlinico Umberto I ( Site 0801)
Rome, Lazio, Italy
Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico ( Site 0805)
Milan, Lombardy, Italy
Humanitas-Medicina interna ed Epatologia ( Site 0800)
Rozzano, Lombardy, Italy
Centro de Investigación y Gastroenterología ( Site 0902)
Cuauhtémoc, Mexico
Arké Estudios Clínicos S.A. de C.V.-Gastroenterology-Hepatology ( Site 0906)
Mexico City, Mexico City, Mexico
Medica Sur-Clinica de Enfermedades Digestivas y Obesidad ( Site 0908)
Mexico City, Mexico City, Mexico
Avix Investigación Clinica, S.C. ( Site 0907)
Monterrey, Nuevo León, Mexico
Centro Multidisciplinario para el Desarrollo Especializado de la Investigacion Clinica en Yucatan (
Mérida, Yucatán, Mexico
Auckland City Hospital-Liver Research Unit ( Site 1003)
Auckland, New Zealand
Middlemore Clinical Trials ( Site 1000)
Auckland, New Zealand
Christchurch Hospital-Gastroenterology Research ( Site 1002)
Christchurch, Canterbury, New Zealand
Nasz Lekarz Przychodnie Medyczne ( Site 1105)
Torun, Kuyavian-Pomeranian Voivodeship, Poland
Centrum Medyczne Pratia Warszawa ( Site 1107)
Warsaw, Masovian Voivodeship, Poland
Clinical Medical Research ( Site 1101)
Katowice, Silesian Voivodeship, Poland
Showing 40 of 69 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.